Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Registry Outcomes Suggest TAVR Roll-Out Has Been Successful So Far

This article was originally published in The Gray Sheet

Executive Summary

The first report from the U.S. TVT Registry of transcatheter aortic valve replacement shows procedural and in-hospital outcomes comparable to those seen in randomized trials and international registries.

You may also be interested in...



LAA Closure Devices: Cardiology Societies Weigh In

In June 2015, three cardiology societies issued a clinical overview on implantation of left atrial appendage closure devices that is the first in a series of documents highlighting the critical issues that need to be addressed in order to integrate these new technologies into clinical practice.

Cardiology Societies Urge Registry For Left-Atrial Appendage Closure Devices

The American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions released an overview of left atrial appendage occlusion devices, specifically Boston Scientific's Watchman and SentreHEART's Lariat.

TAVR May Be A Good Choice For Even Low-Risk Patients, NOTION Trial Shows

So far, transcatheter aortic valves are only indicated for patients for whom surgery presents high or even intolerable risks. Two-year data from a trial in Scandinavia suggests TAVR could eventually supplant surgical valve replacement in patients at low risk during surgery, but this approach will require more study.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel